Importantly, we demonstrated that DCLK1 inhibitor could block CCAR1/β‐catenin pathway‐mediated cancer stemness and consequently suppressed 5‐fluorouracil resistant CRC cells in vitro and in vivo. This evidence concerns the gene DCLK1 and cancer.